Janux Therapeutics (JANX) to Release Quarterly Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Janux Therapeutics to post earnings of ($0.65) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $13.21 on Thursday. Janux Therapeutics has a one year low of $12.12 and a one year high of $38.42. The stock has a market capitalization of $794.58 million, a PE ratio of -7.86 and a beta of 2.88. The business’s fifty day moving average is $13.88 and its 200 day moving average is $21.21.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JANX. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Thursday, January 22nd. Wedbush restated an “outperform” rating and set a $45.00 price objective (down previously from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Clear Str lowered shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Barclays lowered their price target on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Janux Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $60.08.

Insiders Place Their Bets

In other news, insider Charles M. Winter sold 2,401 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $32,965.73. Following the completion of the sale, the insider directly owned 77,721 shares in the company, valued at $1,067,109.33. This represents a 3.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction on Monday, December 1st. The shares were sold at an average price of $32.98, for a total value of $109,922.34. Following the transaction, the insider owned 84,974 shares in the company, valued at $2,802,442.52. This trade represents a 3.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 22,366 shares of company stock valued at $371,245. 8.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in JANX. Osaic Holdings Inc. grew its holdings in Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Janux Therapeutics during the fourth quarter valued at $137,000. Martingale Asset Management L P bought a new stake in Janux Therapeutics in the 4th quarter valued at $155,000. Finally, Federated Hermes Inc. purchased a new stake in Janux Therapeutics in the 4th quarter worth $164,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.